AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer

Days After Green Light For Clovis's Rival PARP

Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.

targets
Lynparza now approved for four tumor types • Source: Shutterstock

Less than a week after Clovis Oncology Inc.'s Rubraca became the first PARP inhibitor approved for prostate cancer, AstraZeneca PLC and Merck & Co. Inc.'s class leader Lynparza has become the second, and the one observers expect to dominate the market.

The US Food and Drug Administration has approved Lynparza (olaparib) for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category